EAM
EBACW

Exos Asset Management’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

Exos Asset Management’s Portfolio EBACW Stock Details EBACW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,100
Closed -$9K – 440
2021
Q3 		$9K Hold
15,100
– – ﹤0.01% 423
2021
Q2 		$14K Buy
+15,100
New +$14K 0.01% 742

Other funds holding EBACW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

Exos Asset Management's EBACW Position: Q4 2021 in Review

Exos Asset Management sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q4 2021, closing a stake of 15,100 shares — an estimated $9K sold.

Exos Asset Management first reported a position in EBACW in Q2 2021 and held it in 2 quarters. The position peaked at $14K in Q2 2021. 30 funds tracked by Wall St. Rank hold EBACW as of Q4 2021.

  • Exos Asset Management reported no remaining European Biotech Acquisition Corp. Warrant position as of Q4 2021 after selling out during the quarter.
  • Exos Asset Management sold 15,100 European Biotech Acquisition Corp. Warrant shares in Q4 2021, an estimated $9K.
  • Exos Asset Management first reported a position in European Biotech Acquisition Corp. Warrant in Q2 2021 and held it in 2 quarters.
  • Exos Asset Management's European Biotech Acquisition Corp. Warrant position peaked at $14K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q4 2021.

Based on Exos Asset Management's 13F filing for Q4 2021, filed 14 Mar 2022.